Mission Statement, Vision, & Core Values (2026) of Piramal Pharma Limited.

Piramal Pharma Limited blends purpose and performance with a clear mission to enhance healthcare through innovation and quality, built since its founding in March 2020 into a global presence spanning 17 locations and serving over 100 countries, offering CDMO services, complex hospital generics and consumer healthcare while committing to reduce Scope 1 and Scope 2 emissions by 42% by FY2030 in line with the Science-Based Targets Initiative; guided by the Piramal Group ethos of "Doing Well and Doing Good" and anchored in the core values of Knowledge, Action, Care, and Impact, PPL pursues ethical growth-combining expertise and innovation, entrepreneurial action with integrity, trusteeship and humility in care, and performance with resilience-to create lasting value for patients, communities, employees, partners and the environment.

Piramal Pharma Limited (PPLPHARMA.NS) - Intro

• Operates across 17 global locations
• Serves customers in over 100 countries
• Maintains a diversified portfolio spanning CDMO services, complex hospital generics, and consumer healthcare

• Patient-centricity - prioritizing safety, efficacy and access
• Scientific rigor - investing in high-quality R&D and regulatory compliance
• Integrity and quality - adhering to global GMP and quality systems
• Collaboration - partnering across industry, academia, and customers
• Sustainability & responsibility - aligning growth with environmental and social goals

• Target: Reduce Scope 1 and Scope 2 greenhouse gas emissions by 42% by FY2030 (aligned to a 1.5°C pathway under the Science-Based Targets Initiative)
• Operational initiatives: energy efficiency, renewable energy procurement, process optimization in manufacturing
• Social commitments: patient access programs, community health initiatives, and employee safety & wellbeing standards

• CDMO - integrated development and manufacturing services for global pharma and biotech customers, including complex APIs and formulation scale-up
• Complex hospital generics - specialized injectable and niche hospital therapies with regulatory approvals across markets
• Consumer healthcare - branded OTC products addressing wellness and consumer health needs

• Scale CDMO capability to capture higher-value, complex projects
• Expand hospital generics portfolio in regulated markets
• Selective M&A and capacity expansion to strengthen global supply resilience
• Drive sustainability to reduce carbon intensity and improve operational efficiencies

Piramal Pharma Limited (PPLPHARMA.NS) - Overview

• Mission focus: Improve patient outcomes via R&D-led innovation, high-quality manufacturing, and accessible therapies.
• Stakeholder remit: Patients, customers, employees, partners, investors, communities, and the environment.
• Ethical posture: Business growth aligned with regulatory compliance, patient safety, and responsible sourcing.
• Operating philosophy: 'Doing Well and Doing Good' - commercial success coupled with social and environmental impact.

• Knowledge - continuous learning via scientific talent, partnerships, and data-driven decision-making; measurable by R&D headcount and spend.
• Action - operational excellence: quality systems, capacity expansion, and regulatory approvals (number of approvals, site certifications).
• Care - patient safety metrics, pharmacovigilance responsiveness, community health initiatives and CSR reach.
• Impact - measurable outcomes: patient reach, therapeutic launches, reduced environmental footprint.

• Therapeutic & product reach: portfolio serving acute and chronic care segments across APIs, advanced intermediates, and finished dosage forms.
• Regulatory/compliance: multiple WHO/GMP and global regulatory approvals enabling exports to regulated markets (US, EU, Canada).
• Community programs: health camps, sanitation and education initiatives targeting thousands of beneficiaries annually through CSR investments.

• R&D pipeline prioritization: focus on high-unmet-need therapies and differentiated delivery systems to improve patient adherence and outcomes.
• Capacity investments: capital expenditure to expand sterile injectables and complex formulation capacity, reducing time-to-market.
• Sustainability integration: energy efficiency, water recycling and responsible sourcing to lower operational footprint while maintaining supply reliability.

Piramal Pharma Limited (PPLPHARMA.NS) - Mission Statement

• Deliver patient-centric therapies and drug-delivery technologies that improve outcomes across geographies.
• Operate with the highest standards of compliance, governance and environmental, social & governance (ESG) responsibility.
• Scale profitable businesses across specialty pharmaceuticals, contract development & manufacturing (CDMO), and consumer healthcare.
• Invest in research and innovation to create enduring pipelines and platform technologies.
• Foster an inclusive workplace and community initiatives consistent with the Piramal Group ethos of 'Doing Well and Doing Good.'

• Scale & Profitability: Target market leadership in chosen therapeutic and manufacturing niches through capacity expansion and margin improvement.
• Innovation-Led Growth: Prioritize platform R&D, biologics and drug-delivery systems to differentiate offerings.
• Sustainability & Ethics: Embed ESG metrics into decision-making-carbon intensity reduction, waste management, and ethical supply chain practices.
• Customer & Patient Focus: Strengthen global commercial capabilities to ensure products reach patients reliably and affordably.
• Resilience & Talent: Build organizational agility and leadership pipelines to sustain multi-decade growth.

• Revenue growth and segmental margin expansion.
• Percentage of revenue from differentiated/innovative products.
• R&D productivity (programs entering clinical/development phases).
• ESG targets: emissions reduction, safety incident rates, community impact metrics.
• Global market share in targeted therapeutic/contract manufacturing categories.

Piramal Pharma Limited (PPLPHARMA.NS) - Vision Statement

• Knowledge: Expertise and Innovation - building differentiated capabilities in drug development, contract development & manufacturing (CDMO), and specialty APIs to solve complex pharmaceutical challenges.
• Action: Entrepreneurship and Integrity - empowering teams to make decisive moves, pursue new market opportunities, and uphold rigorous ethical and compliance standards.
• Care: Trusteeship and Humility - protecting stakeholder interests, prioritizing patient safety and environmental responsibility while maintaining a humble, learning-oriented culture.
• Impact: Performance and Resilience - targeting market leadership in chosen segments, driving sustained profitability, and building businesses that adapt and endure.

• Knowledge - sustained investment in R&D and technical talent to advance complex APIs, formulation science, and biologics services; institutionalized knowledge sharing across global teams.
• Action - entrepreneurial business units empowered with P&L responsibility; fast decision cycles for CDMO project wins and lifecycle management of assets.
• Care - robust quality systems, patient safety protocols, and ESG initiatives focused on emissions, water stewardship, and community health programs.
• Impact - disciplined capital allocation aimed at scalable, high-margin segments; building resilient supply chains and diversified customer portfolios to withstand market cycles.

• Scale differentiated CDMO capabilities to capture higher-value outsourced development and manufacturing mandates.
• Accelerate specialty API pipeline and complex generics with higher barriers to entry.
• Increase operational efficiency and margin expansion through capacity optimization and digital transformation.
• Strengthen governance, compliance, and ESG performance to protect long-term stakeholder value.